drugset
drugset / Trial / NCT07369492

Safety and Efficacy Study of BAFF-R CAR-T Cells in Adult Subjects With CD19-Negative Relapsed or Refractory B-Cell Lymphoma

NCT07369492 ↗

Phase 1 Recruiting 30 enrolled Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and tolerability of BAFF-R CAR-T Cells in Adult Subjects with CD19-Negative relapsed or refractory B-Cell Lymphoma.

Timeline

Start
2026-01-01
Primary completion
2027-01
Completion
2029-01

Drugs

EvaluationDrugModalityDoseRoute
Subject BAFFR-CAR T cells Cell therapy 1e+06 cells/kg Intravenous
Subject BAFFR-CAR T cells Cell therapy 3e+06 cells/kg Intravenous
Subject BAFFR-CAR T cells Cell therapy 9e+06 cells/kg Intravenous
Subject BAFFR-CAR T cells Cell therapy 6e+08 cells Intravenous

Indications

lymphoma